Observational studyMedicine2017
Clinical analysis and prognosis of synchronous and metachronous multiple primary malignant tumors.
Observational study in Medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 75 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
75 citing papers in PubMed, 1 synthesis or guideline pooled it.
- A Rare Synchronous Existence of Warthin's Tumour and Oral Cancer:Sultan Qaboos University medical journal · 2025Pooled it
- Article
- Single-cell RNA sequencing and large-panel NGS analysis reveal transcriptional heterogeneity and genomic characteristics of double primary lung cancer and thyroid cancer.Genes & diseases · 2026Article
- Metachronous primary non-small cell lung cancer and mucinous tubular and spindle cell carcinoma of the left kidney: A case report.Oncology letters · 2026Article
- Long-term survival and successful pregnancy in a Nigerian woman with concurrent diagnosis of non-Hodgkin lymphoma and chronic myeloid leukemia: a case report.Journal of medical case reports · 2026Article
- The risk and prognosis factors of second primary malignancies in hepatocellular carcinoma survivors.Discover oncology · 2026Article
- Long-term durable response to Sintilimab therapy in synchronous lung squamous cell carcinoma and gastric adenocarcinoma: a rare case report.Frontiers in oncology · 2026Article
- Synchronous rectal and endometrial cancer: A case report and literature review.Oncology letters · 2026Article
- Differences of clinical features, prognosis and genetic mutations in Chinese patients with malignant melanoma and additional primary tumours.Annals of medicine · 2025Article
- Synchronous Versus Metachronous Multiple Malignant Tumors Involving the Digestive Tract: Predictors of Survival from a Single-Center Retrospective Study.Medicina (Kaunas, Lithuania) · 2025Article
- Long-Term Survival in a Dog After Adrenalectomy and Splenectomy for Two Different Malignancies with Portal Vein Involvement.Animals : an open access journal from MDPI · 2025Article
- Article
- Synchronous triple-negative breast cancer, rectal adenocarcinoma, and chemotherapy-induced hepatitis B virus reactivation: a case report and review of the literature.Journal of medical case reports · 2025Review
- Long-Term Survival in Metachronous Primary Malignancies: Stage III Nasopharyngeal Cancer and Stage IV Non-Small-Cell Lung Cancer.Journal of clinical medicine · 2025Article
- Multiple primary malignancies and gut microbiome.BMC cancer · 2025Article
- Multiple primary cancers with gastrointestinal malignant tumors as the first manifestation: Three case reports and review of literature.World journal of gastroenterology · 2025Review
- Clinical characteristics of diffuse large B-cell lymphoma complicated with multiple primary malignant neoplasms.Frontiers in oncology · 2025Article
- Primary hepatic leiomyosarcoma concurrent with early-stage lung adenocarcinoma: a rare case report.Frontiers in oncology · 2025Article
- Effect of metachronous primary and secondary solid cancers in patients with multiple myeloma: a retrospective study from a single-center.Frontiers in immunology · 2025Article
- Castleman disease with synchronous primary rectal and prostate cancers: a case report of successful multimodal treatment and 2-year recurrence-free survival.Frontiers in oncology · 2025Article
15 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The aim of this study was to determine the clinical features, treatment factors, and prognosis of patients with multiple primary malignant tumors (MPMTs). In total, 161 patients with MPMTs at our hospital (The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China) were analyzed in this study. We found that among 161 patients with MPMTs, 78 (48.4%) patients had synchronous tumors and 83 (51.6%) patients had metachronous tumors. Most clinical and pathological features were similar in both groups. Most patients with MPMTs were men and older patients (>50 years old), and adenocarcinoma was the most frequent pathology type. The most frequent location of all MPMTs was the digestive system. The leading tumor association was between digestive-digestive tumors, also. However, patients with synchronous tumors and MPMTs of the digestive system showed a shorter survival time. In the metachronous cancer group, the median interval time was 60 months, and a short interval time (≤60 months) was associated with a shorter survival time. In addition, survival time was increased in the younger age group (≤50 years old) and in patients who accepted surgery-based comprehensive therapy. However, only interval time (≤60 months) was an independent prognostic factor associated with survival for the metachronous cancer group. Therefore, careful surveillance and follow-up are especially important in these patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.